Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    J Clin Psychiatry. 2007;68 Suppl 10:4-7.

    Augmenting antidepressants with folate: a clinical perspective.

    Source

    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. mfava@partners.org

    Abstract

    The goal of treatment of depression is full remission, but only a minority of patients will achieve full remission with antidepressant monotherapy. Several forms of augmentation have been found to improve the effect of antidepressants, but in some cases, issues of safety and tolerability may be of concern. Folate in particular has been found to further reduce symptoms in patients with depression when used in conjunction with an antidepressant, and because folate is a water-soluble B vitamin, its safety and tolerability are well established. This strategy would typically be used in patients with low plasma or red blood cell folate levels. Folate augmentation may be used (1) to enhance the efficacy of antidepressants in nonresponders, (2) to enable those who partially respond to antidepressant monotherapy to achieve remission, and (3) to alleviate residual symptoms during antidepressant treatment.

    PMID:
    17900202
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Allen Press, Inc.

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk